About
Laura Brass PhD, MBA is a Managing Director at the Novartis Venture Fund in Cambridge, MA, USA. Prior to NVF, Laura was a Managing Director at MPM Capital and, before that, a member of the founding management team and SVP BD for TriNetX. Laura has held various roles in business development and IP strategy, and was CEO of Aferon, an early-stage antiviral start-up. Laura holds a BA in Philosophy and BS in Biochemistry from the University of Missouri-Columbia, as well as a PhD in Molecular Genetics and Cell Biology and MBA, both from the University of Chicago.
Investments
- Atalanta (Observer)
- Averna Therapeutics (Board Director)
- EpiBiologics (Board Director)
- Protego (Board Director)
- Seawolf (Board Director)
- Sidewinder (Observer)
- Tagworks Pharmaceuticals (Observer)
Successes
- Alesta Therapeutics (M&A)
- Annexon (IPO)
- Immunitas (M&A)